Is it time for developing countries to adopt neonatal pulse oximetry screening for critical congenital heart disease?

Critical congenital heart disease is often missed with resultant death or severe circulatory collapse and morbidity. Pulse oximetry screening has now been recommended for use in the United States of America and adopted in other developed world settings as part of the compulsory newborn screening programme. In this review we detail the rationale behind neonatal pulse oximetry screening, summarise the recent evidence and present data on method, cost-effectiveness and acceptance. However, differences in health systems in the developed world and developing countries are clearly refl ected in the discrepancies in management and outcome of congenital heart disease. We discuss the importance of embedding a neonatal screening programme within local situations and suggest a method, using the infant mortality rate and other neonatal indicators, to position neonatal pulse oximetry screening into existing newborn screening programmes

Management of undernutrition and failure to thrive in children with congenital heart disease in low- and middle-income countries

Poor growth with underweight for age, decreased length/height for age, and underweight-for-height are all relatively common in children with CHD. The underlying causes of this failure to thrive may be multifactorial, including innate growth potential, severity of cardiac disease, increased energy requirements, decreased nutritional intake, malabsorption, and poor utilisation of absorbed nutrition. These factors are particularly common and severe in low- and middle-income countries. Although nutrition should be carefully assessed in all patients, failure of growth is not a contraindication to surgical repair, and patients should receive surgical repair where indicated as soon as possible. Close attention should be paid to nutritional support - primarily enteral feeding, with particular use of breast milk in infancy - in the perioperative period and in the paediatric ICU. This nutritional support requires specific attention and allocation of resources, including appropriately skilled personnel. Thereafter, it is essential to monitor growth and development and to identify causes for failure to catch-up or grow appropriately

Anti-platelet agents in pediatric cardiac practice

Pediatric patients with a variety of congenital and acquired cardiac conditions receive antithrombotic therapy. Many of the indications are empirical, and have either not been proven in controlled studies or are extrapolated from adult studies. This article reviews the current available literature regarding the use of anti-platelet drugs in the pediatric cardiac population

Oral anticoagulants in pediatric cardiac practice: A systematic review of the literature

Recent advances in the pediatric heart surgery, especially the Fontan procedure, has necessitated an increased use of oral anticoagulants in pediatric cardiac patients. Warfarin is the standard agent used for most pediatric indications, though there are very few randomized control studies in children regarding its use. This review summarizes the current indications and evidence base regarding the use of oral anticoagulants in the pediatric age group

Prenatal diagnosis of isolated interrupted inferior vena cava with azygos continuation to superior vena cava

Absence of inferior vena cava is an uncommon congenital abnormality. It is usually associated with other structural anomalies, typically left isomerism. We report a case of interrupted inferior vena cava with azygos continuation diagnosed as an isolated finding during routine prenatal ultrasound scan, confirmed by post-natal echocardiography. Detailed ultrasound examination of the fetal anatomy failed to demonstrate other anomalies. The neonatal course of this fetus was uneventful